医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

 Visioneering Wins Award of Excellence for Its NaturalVue® Multifocal 1 Day Contact Lenses at Australia’s Largest Eyecare Event

2019年07月23日 AM09:00
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

US-based medical device company Visioneering Technologies Inc. (ASX: VTI) (‘Visioneering’ or ‘The Company’) is pleased to announce that it has received the Award of Excellence for its innovative NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses at the O=MEGA 19 event in Melbourne, Australia. O=MEGA 19 is the largest eyecare and eyewear event in Australia, replacing and combining the Southern Regional Congress (SRC) and Optical Distributors & Manufacturers Association of Australia (ODMA) Fair.

NaturalVue Multifocal (NVMF) was selected as the best in innovation and technology among some of the industry’s strongest competitors including Alcon’s Dailies Total 1 Contact Lenses and Bausch & Lomb’s Ultra for Astigmatism. The awards were judged by an expert independent panel consisting of Professor Fiona Stapleton, PhD, UNSW; Steven Daras, Teacher, Optical Dispenser & Course Coordinator TAFE Digital; Richard Banks, Independent Optometrist; and Lyndal Frollano, former Creative Director of Harper’s Bazaar Magazine.

NVMF contact lenses feature Visioneering’s innovative Neurofocus Optics® Technology which employs a patented extended depth-of-focus design. The innovative NVMF lens design allows it to be used for both myopic progression control and presbyopia (the age-related loss of ability to see near objects).

Visioneering’s Senior Vice President, Sales and Marketing, Tony Sommer commented, “We are extremely proud to win the Award of Excellence for Contact Lenses at O=MEGA 19. NaturalVue Multifocal is a significant addition to the myopia toolkit for optometrists, and we thank the judges for recognizing our technological edge.”

Dr. Peg Achenbach, FAAO, Vice President of Professional Services and Clinical Science, was on hand to accept the award on behalf of Visioneering. Dr. Achenbach was at O=MEGA19 to deliver a talk on the topic of: ‘Extended Depth of Focus Contact Lenses – A Novel Approach to Myopia Control’.

O=MEGA19 was established by the ODMA and Optometry Victoria/South Australia. The three-day event brings together leading participants from the global optical industry and comprises a clinical conference, a trade fair and masterclasses.

NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lens Indication for Use in Europe and Australia and New Zealand: NaturalVue (etafilcon A) Multifocal Daily Disposable Soft (Hydrophilic) Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia) and/or presbyopia, and myopia progression control in aphakic and/or non-aphakic persons with non-diseased eyes in powers from -20.00 to +20.00 dioptres and with non-diseased eyes who may require a reading addition of up to +3.00D. The lenses may be worn by persons who exhibit astigmatism of 2.00 dioptres or less that does not interfere with visual acuity.

About Visioneering Technologies Inc.

Visioneering Technologies Inc. (ASX: VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

MKT-ANZ-PR4 r0

View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005735/en/

CONTACT

Layna L. Mendlinger

info@vtivision.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease